Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 10, 2025

WinNonlin

RRID:SCR_024504
Type: Tool

Proper Citation

WinNonlin (RRID:SCR_024504)

Resource Information

URL: https://www.certara.com/software/phoenix-pkpd/

Proper Citation: WinNonlin (RRID:SCR_024504)

Description: Software to automate repetitive analysis steps and is widely considered the industry standard for NCA, TK, and PK/PD modeling. Used as non-compartmental analysis (NCA), pharmacokinetic/pharmacodynamic (PK/PD), and toxicokinetic (TK) modeling tool.

Synonyms: Phoenix WinNonlin

Resource Type: software application, software resource

Keywords: automate repetitive analysis steps, NCA, TK, PK/PD modeling, non-compartmental analysis, pharmacokinetic/pharmacodynamic, toxicokinetic, modeling tool,

Funding:

Availability: Free, Available for download, Freely available

Resource Name: WinNonlin

Resource ID: SCR_024504

Record Creation Time: 20231002T161336+0000

Record Last Update: 20250410T071807+0000

Ratings and Alerts

No rating or validation information has been found for WinNonlin.

No alerts have been found for WinNonlin.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 46 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Kummar S, et al. (2025) First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies. Cancer research communications, 5(1), 94.

Drabison T, et al. (2024) Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen. Cancer research communications, 4(9), 2489.

Koyama T, et al. (2024) Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors. Cancer research communications, 4(9), 2349.

Ahluwalia MS, et al. (2024) A multicenter, phase 1, Adult Brain Tumor Consortium trial of oral terameprocol for patients with recurrent high-grade glioma (GATOR). Cell reports. Medicine, 5(7), 101630.

Glasenapp A, et al. (2024) Subcutaneous and orally self-administered high-dose carprofen shows favorable pharmacokinetic and tolerability profiles in male and female C57BL/6J mice. Frontiers in veterinary science, 11, 1430726.

Ahn DH, et al. (2024) Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(10), 2039.

Zammarchi F, et al. (2024) ADCT-602, a Novel PBD Dimer-containing Antibody-Drug Conjugate for Treating CD22-positive Hematologic Malignancies. Molecular cancer therapeutics, 23(4), 520.

Wright NJ, et al. (2024) Design of an equilibrative nucleoside transporter subtype 1 inhibitor for pain relief. Nature communications, 15(1), 10738.

Galasko D, et al. (2024) A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with Early Alzheimer's Disease. medRxiv : the preprint server for health sciences.

Papacharisi E, et al. (2024) Novel Amanitin-based Antibody Drug Conjugates (ATAC®) targeting TROP2 for the treatment of Pancreatic Cancer. Molecular cancer therapeutics.

Padmapriyadarsini C, et al. (2023) A dose-finding study to guide use of verapamil as an adjunctive therapy in tuberculosis. medRxiv : the preprint server for health sciences.

Hu H, et al. (2023) Comparative study of the plasma pharmacokinetics and tissue residues of trimethoprim in silky fowls and 817 broilers after single oral administration. Poultry science, 102(11), 103060.

Yang Q, et al. (2023) The pharmacokinetics and pharmacodynamics of cefquinome against Streptococcus agalactiae in a murine mastitis model. PloS one, 18(1), e0278306.

Kim MS, et al. (2023) Physiologically Based Pharmacokinetic Modelling to Predict Pharmacokinetics of Enavogliflozin, a Sodium-Dependent Glucose Transporter 2 Inhibitor, in Humans. Pharmaceutics, 15(3).

Shimizu H, et al. (2023) Edaravone Administered Orally and Via Nasogastric Tube in Healthy Adults: A Comparative Bioavailability Phase 1 Study. Clinical pharmacology in drug development, 12(1), 77.

Kanji CR, et al. (2023) Pharmacokinetics of Tamoxifen and Its Major Metabolites and the Effect of the African Ancestry Specific CYP2D6*17 Variant on the Formation of the Active Metabolite, Endoxifen. Journal of personalized medicine, 13(2).

Herrera AF, et al. (2022) Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 28(7), 1294.

Na JY, et al. (2022) Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first-in-class, first-in-human study. Clinical and translational science, 15(11), 2744.

Vandenbossche J, et al. (2022) Drug-Drug Interactions With the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379 (Bersacapavir). Clinical pharmacology in drug development, 11(12), 1419.

Thikekar AK, et al. (2022) Effect of herbal formulation on glimepiride pharmacokinetics and pharmacodynamics in nicotinamide-streptozotocin-induced diabetic rats. Journal of Ayurveda and integrative medicine, 13(3), 100633.